Related Party Transactions

9 Months Ended

Sep. 30, 2017

9.	Related Party Transactions

In April and June 2017, under supply agreements with Spectrum, the Company received shipments of EVOMELA^® and MARQIBO^®, respectively, in China for quality testing purposes to support CASI’s application for import drug registration. The CEO of Spectrum is also a board member of CASI. The total cost of the materials was approximately $477,000 which is included in research and development expense for the nine months ended September 30, 2017.

The Company utilizes the services of Crown Biosciences, Inc. (“Crown Bio”) to perform certain research and development testing. The CEO of Crown Bio is also a board member of CASI. All amounts payable to Crown Bio for services provided have been paid as of September 30, 2017. The research and development expense recognized for the services provided for the nine months ended September 30, 2016 was $28,648. There were no research and development services provided by Crown Bio for the nine months ended September 30, 2017.